| DB ID | MyCo_2391 |
| Title | Biomarkers for the diagnosis of invasive candidiasis in immunocompetent and immunocompromised patients |
| Year | 2021 |
| PMID | 34384954 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | anti-Met6 antibodies |
| Biomarker Full Name | anti-Met6 antibodies |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | Studied 627 sera from 297 patients. Sera were collected prospectively at the Severo Ochoa University Hospital (Legan es-Madrid) and Cruces University Hospital (Barakaldo-Bizkaia), and stored at -20°C. Patients were classified into 3 groups according to clinical, and microbiological data. Group 1 included 126 patients (332 sera) with IC proven by a positive blood culture. Group 2 gathered 66 patients (164 sera) with other fungal infections, mainly Aspergillus, and Pneumocystis infections. Group 3 included 105 patients (131 sera) with no evidence of IFD. Patients were further classified as immunocompetent or immunocompromised. The sera collection is anonymized and registered (C.0005025) at the Instituto de Salud Carlos III, Spain. |
| Cohort No. | 297 Patients |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.92 |
| Specificity | 0.74 |
| Positive Predictive Value | 0.49 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in hospitals of developed countries with a high attributable mortality 40% to 50% despite treatment with antifungal agents. Population-based studies have reported incidence rates of 1.4 to 20 per 100,000 inhabitants. The incidence of IC in immunocompromised patients has increased as a consequence of factors such as long-term hospitalization, acquired immunodeficiency (HIV infection), treatment-induced immunodeficiency in patients receiving hematopoietic stem-cell or solid organ transplants, as well as those undergoing anticancer therapy. These patients can not eliminate efficiently this opportunistic and commensal fungus. Furthermore, IC also extends the length of hospital stay and increases the cost of medical care. |
| Technique | Immunological assay |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA- Fungitell kit -Associates of Cape Cod, Inc, E. Falmouth, MA, USA |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
